This retrospective study used whole-genome sequencing to catalogue targetable alterations across solid tumour types. Data came from 11 013 primary tumours of 19 types in the UK and 6016 metastatic tumours in the Netherlands. Immediately actionable alterations were found in 18·9% of primary and 25·9% of metastatic cancers. A further 10·9% of primary and 14·4% of metastatic cancers had investigational alterations or signature-informed features. Of 5706 immediately actionable variants, 51·1% lay in tumour types without US FDA approval for that biomarker. The main limitation is the retrospective design, and the abstract reports no treatment outcomes.
Why it is interesting: About half of immediately actionable variants sat in tumour types where the matching biomarker lacks FDA approval. The pan-tumour scale shows how much actionable biology current tumour-specific approvals leave uncovered.
Abstract — the authors' own words, CC BY
Background
The clinical application of precision oncology therapies is currently restricted to selected cancer cases harbouring highly specific mutations. Targeted therapies are typically approved for use in specific tumour types in which these alterations occur frequently. We aimed to systematically catalogue targetable alterations and genome-wide biomarkers across all solid tumour types to identify additional therapeutic opportunities. Methods
In this retrospective, pan-solid tumour analysis, for the primary cancer cohort, we used matched fresh frozen tumour and normal DNA samples and anonymised patient metadata from a discovery cohort of 11 013 tumours comprising 19 tumour types collected from 10 334 participants in the UK-based 100 000 Genomes Project (100kGP). Participants were recruited to this cohort through 13 National Health Service Genomic Medicine Centres or hospitals affiliated to the 100kGP between 2012 and 2019. For the metastatic cancer cohort, we used matched tumour and normal DNA samples and anonymised patient metadata from a cohort of 6016 solid tumours collected from 5658 patients from the Netherlands who contributed to the Hartwig Medical Foundation (HMF) database (accessed Aug 19, 2025). Snap-frozen tumour DNA and matched normal DNA from blood samples underwent whole-genome sequencing. Potentially targetable alterations, comprising (1) immediately actionable alterations, (2) investigational alterations, and (3) mutational signature-informed features, were sought in all samples. The primary outcome of this study was to assess the pan-cancer frequency and tissue distribution of potentially targetable alterations. Findings
Between July 1, 2025, and March 3, 2026, we analysed samples from 17 029 tumours from the 100kGP and HMF cohorts. Immediately actionable alterations were identified in 2081 (18·9%) of 11 013 primary and 1559 (25·9%) of 6016 metastatic cancers; a further 1204 (10·9%) primary and 867 (14·4%) metastatic cancers harboured investigational alterations or mutational signature-informed features. 2914 (51·1%) of the 5706 immediately actionable variants identified were found in tumour types where the biomarker is not approved by the US Food and Drug Administration. Although some immediately actionable alterations (including gene-fusion targets and MET exon 14 skipping variants) were restricted to fewer tumour types, most immediately actionable alterations (including HER2 amplification, RAS-RAF pathway alterations, IDH1 mutations, and DNA repair deficiencies) occurred across multiple tumour types, frequently beyond those for which matched targeted therapies are currently approved. Mutational-signature biomarkers of DNA repair or replication deficiencies were similarly observed across tumour types. Metastatic cancers, including rare and moderately rare tumour types and cancers of unknown primary, harboured a notably high prevalence and diversity of targetable events. Interpretation
Our findings support comprehensive whole-genome sequencing assessment of cancers irrespective of tumour type. Prospective clinical trials are required to establish whether therapeutic vulnerabilities identified by whole-genome sequencing can extend the effective use of targeted therapies beyond their current tumour-specific indications. Funding
Cancer Research UK, Breast Cancer Research Foundation, National Institute for Health and Care Research, Jeffrey Cheah Foundation.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.